MyoKardia Inc MYOK 1.87%, a thinly traded mid-cap biotech, is on the radar of investors ahead of the company's scheduled presentation at the European Society of Cardiology Congress Aug. 31-Sept. 4 in Paris.
The South San Francisco, California-based biotech, founded in 2012, uses a precision medicine approach to discover and develop targeted therapies for serious and neglected rare cardiovascular diseases.
a pharmaceutical company which develops drugs for genetic cardiovascular diseases
Industry NotClassified